sorafenib has been researched along with lamivudine in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (lamivudine) | Trials (lamivudine) | Recent Studies (post-2010) (lamivudine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7,025 | 1,425 | 2,177 |
| Protein | Taxonomy | sorafenib (IC50) | lamivudine (IC50) |
|---|---|---|---|
| Capsid protein | Hepatitis B virus | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, W; Gu, X; Guan, M; Huang, X; Li, X; Qiu, J; Zhang, Y; Zhao, Y; Zhou, Q; Zou, Y | 1 |
1 review(s) available for sorafenib and lamivudine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and lamivudine
| Article | Year |
|---|---|
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Viral; Hepatitis B virus; Humans; Liver Neoplasms; Quinazolinones; Virus Replication | 2020 |